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Abstract: Shiga toxins and ricin are well characterized similar toxins belonging to quite 
different biological kingdoms. Plant and bacteria have evolved the ability to produce these 
powerful toxins in parallel, while humans have evolved a defense system that recognizes 
molecular patterns common to foreign molecules through specific receptors expressed on 
the surface of the main actors of innate immunity, namely monocytes and neutrophils. The 
interactions between these toxins and neutrophils have been widely described and have 
stimulated intense debate. This paper is aimed at reviewing the topic, focusing particularly 
on implications for the pathogenesis and diagnosis of hemolytic uremic syndrome. 
Keywords: Shiga toxins; ricin; ribosome-inactivating proteins; polymorphonuclear 
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1. Shiga Toxins and Ricin Are Analogous Toxins 
It is intriguing that two quite different biological kingdoms have evolved, in parallel, the ability to 
produce powerful cytotoxins with the same mechanism of action and structural similarity, such as 
Shiga toxins (Stx) from bacteria and ricin and related toxins from plants. Ricin is a potent toxic 
molecule known since 1888 when this name was coined for the proteinaceous and toxic substance 
derived from the seeds of Ricinus communis (castor beans), also capable of agglutinating 
erythrocytes [1]. Ricin is a bipartite exotoxin consisting of two disulfide-bonded chains: a single  
B-subunit (34 kDa) with galactose-binding properties and a single A-chain (32 kDa) endowed with the 
enzymatic activity [2]. Many glycoproteins and glycolipids present on the eukaryotic cell surface 
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contain galactose residues that are specifically recognized by the lectin B chain, which allows binding 
to cells and facilitates endocytosis. Thus, the cytotoxicity of ricin is rather non-specific. 
The first demonstration of the primary cellular function inhibited by the toxin A chain was obtained 
in neoplastic cells [3]: ricin strongly affected protein biosynthesis, while DNA synthesis was only 
slightly impaired, and the uptake of amino acids and RNA synthesis were spared. This result was 
confirmed shortly afterwards in the rabbit reticulocyte cell-free protein synthesis system, in which very 
small amounts of ricin completely inhibited translation [4]. The latter data were obtained by using 
whole ricin, i.e., the two disulfide-linked A and B polypeptide chains. The reduction of the disulfide 
bridge was found to induce opposite effects on the action of ricin on cell-free systems and on mice [5]. 
The inhibitory effect on cell-free translation in vitro was markedly enhanced by the treatment, whereas 
the toxic effect on mice was strongly reduced, indicating different biological functions for the two 
chains, i.e., the requirement of the lectinic B-chain to mediate entry of the toxin into cells, and of the 
free A chain to inhibit protein synthesis. In 1973, the ribosome [6] and more precisely the 60S 
subunit [7] were identified as the macromolecular targets of the A chain of ricin within the protein 
synthesis machinery. It was subsequently found that the damaged ribosomes were unable to bind 
elongation factors [8,9], thus pinpointing the functional ribosomal impairment. The calculation of the 
kinetic constants of ribosome inactivation by ricin A chain (Km = 0.2 µM, Kcat = 1400 ribosomes 
modified/min) produced final evidence for the enzymatic action of the toxin [10]. 
The specific enzymatic activity of ricin on ribosomes was elucidated after more than a decade by 
Endo and collaborators [11,12] who showed that treatment of rat liver ribosomes with ricin A chain 
induced removal of adenine in position A-4324, by specific cleavage of the bond linking the purine to 
ribose (N-glycosidic bond). This specific residue is located in a stem-loop region of the 28S rRNA, 
which is one of the most strongly conserved rRNA sequence (5′-AGUACGAGAGGA-3′ in bold the 
adenine removed by ricin), present in almost all living species, from bacteria to eukaryotes [13]. 
Elegant footprinting experiments [14] have clearly demonstrated that this sequence is part of the 
recognition binding sites (consensus sequence) for prokaryotic (EF-Tu, EF-G) and eukaryotic 
(eEF-1, eEF-2) elongation factors. Since many different proteins capable of inactivating ribosomes 
were isolated in different plant species, they were systematically assayed for the ability to remove 
adenine from eukaryotic ribosomes. All of them shared the same enzymatic activity [15]; henceforth, 
these enzymes were officially classified as rRNA N-glycosidases (EC 3.2.2.22.) and the denomination 
ribosome-inactivating proteins (RIPs) was coined.  
In the meantime, Shiga toxin from Shigella dysenteriae, the etiological agent of bacillary dysentery, 
was found to be a potent inhibitor of protein biosynthesis in cells [16–18] and in cell-free systems [19]. 
A breakthrough in the field was the purification to homogeneity of microgram amounts of the bacterial 
toxin obtained in 1980 [20], and evidence of the selective enzymatic inactivation of the 60S eukaryotic 
ribosomal subunit by purified Shiga toxin [21]. A few years later, the same Japanese researcher who 
had discovered the molecular mechanism of action of ricin, produced evidence that Shiga toxin and the 
related Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) (see below) removed the same adenine as did 
ricin from 28S rRNA [22]. Thus, bacteria and plants have probably converged during evolution to 
produce toxic molecules acting on this Achilles’ heel of ribosomes. However, ribosomal RNA is not 
the sole intracellular substrate of these toxins. All plant RIPs and Stx tested have been found to remove 
multiple adenines from DNA in vitro [23–25]. The early nuclear DNA damage observed in human 
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endothelial cells challenged with ricin and Stx might be relevant to the mechanism of intoxication and 
constitutes a further convergence for plant and bacterial RIPs [26,27]. These common enzymatic 
behaviors are justified by the structural similarity between ricin and Shiga toxin deduced from their 
crystal structures [28,29]. The A region of Shiga toxin harboring the active site (A1 fragment, see 
below) and the A chain of ricin show high levels of similarity, whereas the B chains of these toxins are 
quite different [28,29]. Indeed, the folds of these A subunit regions that have 149 structural equivalent 
residues (23% of them identical) are nearly superimposable (Figure 1) [28,29]. 
Figure 1. Folding of the A chain of ricin, compared to the A1 fragment from Stx [30]  
(with permission from Elsevier). 
 
Seven of the invariant residues (Tyr-77, Val-78, Ser-112, Tyr-114, Glu-167, Ala-168, Arg-170, and 
Trp-203; numbers as in Shiga toxin) are present in the active site cleft and some of them interact 
directly with adenine forming hydrogen bonds (Val-78, Ser-112, Tyr-114, and Arg-170; numbers as 
above) allowing the recognition of the substrate [28,31–33]. Thus, ricin and Stx share structural 
similarities, the same enzymatic activity and different binding specificity for eukaryotic cells. 
2. Pro-Inflammatory Cytokines Produced by Eukaryotic Cells in Response to Ricin and Stx  
Many authors have demonstrated independently that treatment of different cell types with ricin 
induces a specific response leading to increased mRNA levels and protein expression of pro-inflammatory 
cytokines such as TNF-α (tumor necrosis factor-α), IL-1β (interleukin-1β), IL-8 [34–37]. Such response 
patterns might contribute to ricin intoxication through the recruitment of inflammatory cells in the 
target organs. A relationship between the enzymatic activity of ricin and gene up-regulating effects might 
be envisaged in view of the fact that sequence-specific 28S rRNA injuries induced by ricin trigger the 
activation of the stress-activated protein kinases JNK (Jun N-terminal kinase) and p38 MAP (p38 
mitogen activated protein) [38,39] which are implicated in the up-regulation of these pro-inflammatory 
genes [35,36,39,40]. In fact, it is recognized that 28S rRNA constitutes a ribo-sensor involved in the 
response of cells to various other stimuli converging on ribosomes, such as UV irradiation and 
antibiotics [38,39].  
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It should be noted that very similar gene up-regulating effects have been observed in the case of Stx 
acting on intestinal epithelial cells, endothelial cells and monocytes [35,37,41–43] and it has thus been 
suggested that these pro-inflammatory molecules are involved in the pathogenesis of human diseases, 
such as hemolytic uremic syndrome (HUS, see below), consequent to infections by bacteria producing 
Stx [44]. In particular, chemokines such as IL-8 and MCP-1 (monocyte chemoattractant protein-1) [42] 
and cell adhesion molecules [45] are up-regulated in endothelial cells intoxicated with Stx. These 
interesting observations were extended by microarray experiments showing that only 24 or 25 human 
genes, out of thousands tested, appeared to be up-regulated by Stx2 and Stx1, respectively [46]. 
Moreover, these genes encode mediators associated with inflammation, probably contributing to the 
recruitment of leukocytes in target organs of diseased patients [46]. Finally, Stx2 showed stronger  
up-regulating effects than Stx1 [27,46], and this might provide the molecular explanation of the 
epidemiologic association between Stx2-producing Escherichia coli strains and Hemolytic Uremic 
Syndrome (HUS) [47,48]. Also, in the case of Stx, the enzymatic activity of the A chain seems to be 
involved in triggering the up-regulating effects via activation of the ribotoxic stress, since treatment of 
cells with non-toxic Stx mutant [49] or challenge with monoclonal antibodies to Stx receptors or with 
purified Stx B chains [50] did not elicit those effects. However, identical impairments of translation 
and overlapping time courses of ribotoxic stress were observed for both Stx variants acting on human 
endothelial cells, so further regulations are probably operative in intoxicated cells, which enhance the 
Stx2-induced up-regulating effects [27].  
In conclusion, as shown in the scheme (Figure 2), the main molecular link between cytokine 
expression and the enzymatic action of ricin and Stx is the ribosome, since the specific damage of 
ribosomal 28S RNA induced by the toxins is indispensable and sufficient to activate stress kinase 
cascades [27,35,36,39,40,51]. This, in turn, induces the nuclear transcription of pro-inflammatory 
genes via activation of appropriate transcription factors, such as NF-kB (nuclear factor kappa B) and 
AP-1 (activator protein-1) [42,50]. However, the same ribosomal damage might interfere with the 
translation into proteins of the pro-inflammatory cytokine mRNAs. Therefore, the relationship between 
cytokine expression and protein synthesis inhibition is quite complex, as a balance needs to be reached 
between the ribotoxic stress that activates transcription and the inhibition of protein synthesis that 
would in turn impair the expression. For this reason, the amount of pro-inflammatory mediators 
released by intoxicated cells progressively increases as the concentrations of ricin or Stx approach the 
IC50 on protein synthesis, whereas when toxin concentrations rise over the IC50, the production of  
pro-inflammatory substances is dampened or even blocked, due to an almost total impairment of 
translation [27,37]. This is the paradox of two potent inhibitors of protein synthesis, which, however, 
induce the regulated and specific expression of proteins.  
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Figure 2. Relationship between ribotoxic stress and expression of pro-inflammatory 
cytokines involved in the pathogenesis of HUS. Ribotoxic stress imposed by Stx (point 1) 
triggers the activation of stress kinase pathways (point 2) culminating in the transcription 
of several pro-inflammatory cytokine mRNAs (point 3). The fate of these messengers is 
strictly related to the level of Stx-induced ribosomal damage that may affect the translation 
into proteins (point 4) of these important mediators of inflammatory damage in HUS. 
 
3. Role of Stx in the Pathogenesis of HUS 
Several excellent reviews have outlined the main steps of the pathogenesis of STEC (Stx-producing 
Escherichia coli) infections as follows. The present review is aimed at showing the role of 
neutrophils/Stx interaction in this context, with an attempt to account for the conflicting results.  
STEC constitute a public health concern because they can cause food- or waterborne illness, whose 
clinical spectrum in humans ranges from mild to more severe manifestations, such as diarrhea, 
hemorrhagic colitis and HUS [52–55]. Most HUS cases are the life-threatening sequela of STEC 
intestinal infections [52–55] and the toxins produced by these bacteria have a causative role in the 
pathogenesis of HUS [56]. This syndrome represents the most common cause of acute renal failure in 
early childhood, being also characterized by thrombocytopenia and microangiopathic hemolytic 
anemia [54,57,58]. STEC strains elaborate Stx1 and Stx2: the two main antigenically distinct variants 
of Shiga toxin produced by Shigella [56]. Stx1 differs from Shiga toxin by a single amino acid in the  
A chain [59], whereas Stx2 has less than 60% similarity with Shiga toxin [56,58]. The toxins are 
composed of a B chain (7.7 kDa) organized in a doughnut-like pentamer which enables binding to the 
specific cellular receptor, the glycolipid globotriaosylceramide (Gb3Cer) [56,58]. The single A chain 
(32 kDa) is responsible for the enzymatic activity whose maximal expression is dependent on the 
proteolytic cleavage induced by the cellular protease furin and by reduction of the disulphide bond 
connecting the two resulting fragments A1 (28 kDa) and A2 (4 kDa) [56,58]. While the latter fragment 
dips its COOH-terminus into the center of the B-pentameric ring, non-covalently connecting the 
different chains of the holotoxin [28], the A1 fragment possesses the enzymatic deadenylating activity 
and directly induces intracellular injuries [56,58]. In humans, only a restricted subset of cells harboring 
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Gb3Cer are targeted by Stx. Microvascular endothelial cells in the kidney, the intestine and the brain 
express Gb3Cer and, even though the toxins also damage mesangial cells and tubular epithelial cells in 
the kidney, endothelial injury is considered the main pathogenic event in HUS [56,60]. Targeted 
endothelial and non-endothelial cells showed a broad spectrum of responses including the production 
of pro-inflammatory cytokines involved in HUS pathogenesis (as reviewed above) [60,61] and the 
triggering of the apoptotic program [62–64]. In the latter case, multiple pathways seem involved, such 
as Stx-mediated ribotoxic stress, Stx-induced DNA damage, B chain interaction with cell receptors and 
endoplasmic reticulum stress response activated by altered host proteins or unfolded A1 fragments in 
intoxicated cells, with consequent imbalance of pro- and anti-apoptotic Bcl-2 (B-cell lymphoma-2) 
proteins [62–64].  
After STEC ingestion and a short incubation time (approximately 3–5 days), the initial symptoms 
(abdominal cramps and diarrhea) are manifested by patients [52,53,56,57]. These symptoms are 
probably not related to the action of Stx, but are rather caused by the characteristic mechanism of 
adhesion of these E. coli strains to the gut mucosa [65,66]. Indeed, these bacteria possess the Type III 
secretion system encoded on the LEE (locus for enterocyte effacement) pathogenicity island. This 
molecular syringe is responsible for the injection in the enterocytes of LEE and non LEE-encoded 
effectors allowing the bacterial colonization of the mucosal epithelial cells of the bowel [67]. This 
results in the intimate adhesion of STEC to the gut mucosa and in the characteristic “attaching and 
effacing” cytopathology [56,60]. The intestinal brush border is disrupted and the enterocytes in 
intimate contact with the bacteria lose microvilli and accumulate cytoskeletal components forming 
structures known as pedestals beneath the cell surface [56,60]. This complex series of events might be 
sufficient to produce non-bloody diarrhea, without necessarily invoking a role for Stx. It should be 
noted that several STEC serotypes that are not associated with HUS are LEE positive [67], thus the 
virulence factors causally involved in the initial symptoms of STEC infections are not sufficient to 
trigger HUS.  
Stx produced by STEC are encoded by genes located on genomes of bacteriophages that occur in 
these bacteria as prophages. Effective expression of toxin genes requires prophage induction and 
subsequent lytic development of the bacteriophage [68]. When this happens, adherent bacteria produce 
Stx that are released in the intestinal lumen. The non-invasive bacteria are confined to the gut, whereas 
their toxins can translocate across the polarized epithelium of the bowel into the circulation. Although 
a contrary report has been recently published [69], a large body of evidence indicates that human 
intestinal epithelial cells do not express Gb3Cer nor other Stx receptors as reviewed in [70]. In 
contrast, human colon carcinoma cell lines showed high Gb3Cer expression and this renders Stx 
suitable for targeted cancer therapy [71,72]. Moreover, sophisticated methods such as Stx TLC  
(thin-layer chromatography) overlay assays followed by MALDI (matrix-assisted laser 
desorption/ionization) mass spectrometry confirmed only scant expression of Gb3Cer in surgical 
specimens of human normal colon [70,73]. However, this expression is not restricted to enterocytes, 
since minor cellular components expressing Gb3Cer are present in the human gut mucosa (Paneth 
cells) and might be involved in Stx translocation across the intestinal epithelium [70]. It is worth 
noting that Stx can reach the gut lamina propria also by Gb3Cer-independent mechanisms: (i) uptake 
of toxins induced by the macropinocytotic activity of intestinal epithelial cells [74], (ii) disruption of 
intestinal epithelial tight junctions induced by STEC/enterocyte interactions [70] or, at a later time, by 
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the opposite transmigration of polymorphonuclear leukocytes (PMN) in the inflamed intestine [75,76]. 
Independently of the mode of translocation through the gut epithelial barrier, having arrived in the 
lamina propria, some Stx molecules are trapped by the Gb3Cer receptors present in the endothelial 
cells lining the microvasculature of the gut [70,73]. Intoxication of these cells could explain the typical 
histopathological changes observed in the gut: hemorrhage and edema of the lamina propria with focal 
areas of necrosis [60,61,77,78]. This scenario also explains the bloody-diarrhea experienced by 
approximately one-third of STEC-infected patients who develop hemorrhagic colitis [52,53,56,57].  
About a week after the onset of diarrhea, HUS occurs in a variable percentage of  
patients (10–25%) [52,53,56,57]. During this phase, the Stx molecules escaping the binding to 
intestinal endothelia reach the Gb3Cer-containing endothelial cells of the microvasculature of the brain 
and the kidney. Under normal conditions, endothelia are not adhesive for platelets and the prevalent 
behavior is thromboresistance. However, in the presence of Stx these properties dramatically change, 
resulting in endothelial dysfunction. Endothelial cells in renal glomeruli alter their adhesion properties 
and produce pro-inflammatory cytokines and chemokines [60,61,78]. The damage to endothelium and 
the induction of pro-inflammatory mediators triggered by Stx is causally related to microvascular 
thrombosis in the kidney [60,61,78]. Histologically, HUS is characterized by widespread thrombotic 
microvascular lesions in the renal glomeruli, the gastrointestinal tract and other organs, such as the 
brain [56,77–79]. The examination of glomeruli from patients with HUS revealed capillary wall 
thickening, swelling and detachment of endothelial cells from the basement membrane exposing  
sub-endothelial matrix [56,77–79]. Under these conditions, circulating platelets promptly adhere to the 
subendothelial matrix, thus becoming activated, and bind to one another (aggregation) with the 
deposition of fibrin. The widespread formation of glomerular microthrombi by narrowing the vascular 
lumen might compromise blood supply determining acute renal failure, the main hallmark  
of HUS [56,60,78].  
The strong reduction in circulating platelets observed in HUS is believed to be caused by both the 
direct and indirect effects of toxins [60,78,80]. Although the matter has been widely debated, several 
lines of evidence indicate that Stx, besides activated platelets [81], can directly interact with resting 
platelets leading to their activation, changes in ultramorphology, increased fibrinogen binding activity 
and aggregation [82]. Platelet aggregates are removed by the reticuloendothelial system, hence 
reducing the number of circulating thrombocytes. In addition, the massive engagement of platelets in 
the damaged microvasculature of the kidney might further contribute to thrombocytopenia [60,78,80]. 
It has been recently shown that Stx, in cooperation with bacterial lipopolysaccharide (LPS), induced 
the formation of aggregates between leukocytes and platelets, leading to a release of tissue  
factor–bearing microparticles. Complement activation on these complexes and on microparticles might 
indicate their role in the prothrombotic state occurring in HUS [83,84].  
Finally, the hemolytic anemia, the third component of the triad that characterizes HUS, is assumed 
to be the consequence of the mechanical injury induced by microthrombi to the erythrocytes passing 
through narrowed renal capillaries. This process results in the formation of schistocytes and helmet 
cells and their sequestration by the reticuloendothelial system [56,60,78]. Thus, Stx are critical 
virulence factors in the development of HUS, as well as in triggering hemorrhagic colitis. However, 
only a few STEC serotypes, in particular O157, O26, O111, O103 and O145, are associated with HUS, 
suggesting that a critical combination of bacterial factors must cooperate with toxins in triggering  
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HUS [67,85]. On the other hand, ricin-injected mice and rats develop the hallmarks of HUS [40,86,87] 
and the latter syndrome was noted as an adverse effect during treatment of cancer  
patients with ricin-containing immunotoxins [88]. This further corroborates the view that ricin and Stx 
are also analogous in inducing peculiar and distinctive afflictions in humans. Obviously, the complex 
series of bacteria/host interactions occurring during the natural course of STEC infections that allow 
the bacterial toxin to reach circulation in humans is not entirely replicated by the experimental or 
therapeutic injection of the whole plant toxin or of its enzymatic moiety in animals or patients, 
respectively. As previously stated, these toxins showed structural similarity and functional identity in 
their A chains, rather than in B chains. This is in keeping with the idea that some crucial steps in the 
development of HUS involve the active chains, whose role could not be simply related to their 
enzymatic activity.  
4. Transport of Stx in Blood and the Role of Stx/PMN Interactions 
Since systemic toxemia is considered to be central to the genesis of HUS, many authors tried to 
demonstrate the simplest hypothesis to explain why STEC confined to the gut might determine kidney 
and brain intoxication, i.e., the movement of free toxins in blood. However, Stx was never detected in 
the sera of HUS patients with concomitant detectable fecal toxin [52,89,90]. In the fundamental study 
by Karmali’s group [52] in which the authors provided the first demonstration of the association 
between HUS and STEC infections, sera from 27 STEC-infected patients with overt HUS were tested 
by Vero cell cytotoxicity assay with negative results, even though 50% of them showed free fecal Stx 
and sampling times for feces and serum were basically the same. Two subsequent studies confirmed 
the absence of Stx in sera from 37 (Vero cell cytotoxicity assay) [89] and 34 (human umbilical vein 
endothelial cell radioactive protein synthesis assay) [90] STEC-infected HUS patients. In the last 
study, it was also demonstrated that the cytotoxic activities of Stx1 and Stx2 added to blood from 
healthy donors were completely recovered after the preparation of sera and did not change after 
prolonged incubation at room temperature, nor after repeated freezing and thawing cycles. Although 
blood from patients with fully developed HUS did not contain detectable amounts of free Stx, a 
fleeting appearance of the toxins in blood followed by a rapid clearance before the onset of renal 
failure cannot be ruled out.  
The second hypothesis to explain the delivery of Stx is the shuttling by macromolecular or cellular 
blood components. In theory, it would seem unnecessary for toxins entering the circulation to initially 
find a receptor on circulating cells or a binding site on a macromolecule rather than going directly to 
the receptors of target cells in kidney and brain. However, there is evidence for this idea that Stx 
interact with various blood cells. In vitro experiments produced evidence of Stx binding to 
erythrocytes [91], monocytes [41,92], platelets [81,82,93] and lymphocytes [94].  
In the human P group system the antigen Gb3Cer, namely Pk, is present on the very rare Pk1 and 
Pk2 phenotypes, rendering the corresponding erythrocytes capable of binding Stx. In addition, the 
erythrocytes belonging to the more common P1 (80–95% of the population) and P2 (most of the 
remaining) groups possess small amounts of the Gb3Cer/Pk antigen. Indeed, Stx were found to bind to 
red cells having P1 and P2 phenotypes [91]. However, direct binding of Stx to erythrocytes was not 
observed in cases of human STEC-induced disease.  
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Human monocytes express small amounts of Stx receptors that appeared related to, but different 
from, the Gb3Cer lipoforms present on endothelial cells [41]. The number of binding sites on 
monocytes might be enhanced by activation after treatment with bacterial endotoxins [41]. The 
monocyte/Stx interactions induce the secretion of the pro-inflammatory mediators TNF-α  
and IL-1β [41]. The latter by up-regulating Gb3Cer receptor expression enhance the sensitivity of 
endothelial cells to the toxins [95–97]. However, the passage of Stx from monocytes to endothelial 
cells does not occur [92], since both cells harbor receptors with similar affinities [41].  
Platelets bind Stx through Gb3Cer and a different glycosphingolipid, namely band 0.03, but the 
distribution of these platelet receptors in humans is quite heterogeneous [93]. Moreover, Gb3Cer 
expression on resting platelets is very low [81], and platelets internalize Stx within 2 h, with 
consequences such as aggregation, changes in ultramorphology and increased fibrinogen binding 
capacity [82]. As stated above, it is reasonable to conclude that direct binding of the toxins to platelets 
might be involved in the prothrombotic state, leading to the thrombocytopenia seen in HUS, rather 
than in the passive transfer of Stx to other body sites.  
Gb3Cer is also expressed on the surface of a narrow range of committed B lymphocytes present in 
germinal centers and on the corresponding B cell lymphomas, such as Burkitt lymphoma[98]. This 
subset of human B lymphocytes is susceptible to the cytotoxic action of Stx [94] and this would tend to 
rule out the hypothesis that B lymphocytes are carriers of Stx in vivo.  
A breakthrough in this scenario was the discovery of the role of PMN in binding Stx and in 
transferring them to endothelia [99]. PMN have been considered of prime pathological importance in 
HUS for different reasons: a high neutrophil count at presentation is a typical finding in patients with 
HUS, and this was found to be strictly related to an adverse outcome in the infected children [100–102]. 
Neutrophils in HUS patients are activated and degranulated as inferred by the presence in the blood of 
patients of high levels of elastase, a protease present in azurophil granules of PMN [103], and also by 
the direct observation of the functional state of PMN in HUS patients [104–106]. PMN degranulation 
and activation also correlate with poor prognosis [104,107] and PMN from HUS patients are more 
adhesive to cultured endothelial cells than to control cells and are directly implicated in experimental 
endothelial injuries in vitro [108]. Since PMN emerged as main actors in the pathogenesis of HUS, it 
was no surprise that they could bind Stx in vitro [99]. The authors of this pivotal paper led by Victor 
van Hinsbergh (corresponding author) and Leo Monnens reported impressive evidence of Stx binding 
to PMN. They found by direct flow cytometric analysis and direct immunohistological studies that the 
addition of fluorescent Stx1 to human whole blood or to purified PMN, erythrocytes, monocytes, 
platelets and lipoproteins resulted in specific binding to PMN and negligible binding to other blood 
components. Thus, for the first time, a careful, comparative quantitative analysis was performed. 
Moreover, by using iodinated Stx1, they calculated, using Scatchard plot analysis, the dissociation 
constant (Kd = 10–8 M) of the interaction PMN/Stx1 and the number of binding sites per cell  
(2.1 × 105). Furthermore, the lack of the internalization of the toxic radioactive cargo by PMN was 
clearly demonstrated. This latter behavior, together with the 10-fold lower affinity of Stx for PMN 
compared to Gb3Cer (Kd = 10–9 M), led the authors to hypothesize a transfer of the toxic ligand from 
these leukocytes to the glomeruli of the patients. The transfer was experimentally demonstrated in vitro 
after incubation of PMN carrying Stx with human glomerular vascular endothelial cells (i) with 
fluorescent toxin by flow cytometric analysis, and (ii) with native toxin by cytotoxicity and protein 
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synthesis radioactive assays. An important point addressed by the authors was the demonstration that 
the transfer of the toxin or the appearance of considerable effects on endothelial cells (toxicity, 
inhibition of translation) occurred after stimulation with TNF-α, a treatment known to enhance the 
expression of Gb3Cer on these cells [95–97]. However, a few years later, some of these authors led by 
Leo Monnens reversed their position, by claiming that the binding of Stx to PMN was not specific and, 
basically, re-interpreting their previous results as artefacts [109]. On the one hand, this dampened the 
enthusiasm for this interesting explanation of the mode of delivery of Stx from the lamina propria of 
the bowel to the endothelia of brain and kidney and, on the other hand, it stimulated scrutiny and 
intense debate on this topic. At the present time, there is no consensus in the literature for a variety of 
sound reasons along with some preconceptions. The sound reasons are based on the conflicting results 
obtained by different groups over the last decade on the binding of Stx to PMN and on the functional 
consequences of such a binding. However, the preconceptions that Stx/PMN interactions are unreliable 
or non-specific or of little biological significance have been widely diffused, leading to some ostracism 
by the scientific community. Leaving out the publications of my group, many sound articles have been 
written on this topic with clever hypotheses, clear-cut experimental plans involving well-conducted 
and technically sound experiments, leading to well-founded deductions that, unfortunately, have led to 
opposite conclusions. This does not necessarily mean that the results are unreliable or flawed;  
rather, it should prompt the scientific community to investigate the matter in more detail to reveal  
the explanation. 
In this review, first the papers in which direct evidence of Stx binding to PMN has been sought will 
be considered. Then the articles reporting indirect positive or negative evidence of such a binding will 
be reviewed. It is worth noting that the first questioned paper published on Blood [99] was never 
retracted by the corresponding author. To the best of my knowledge, no item of that paper was proven 
to be fraudulent or derived from incorrect experiments or misleading interpretations. It should also be 
noted that very similar experimental techniques had been employed by the same scientists who 
authored the Blood paper demonstrating the binding of Stx to monocytes without stimulating any 
further criticism [41]. Thus, the results reported on the Blood paper should be considered as evidence 
supporting the reliability of Stx/PMN interactions, whereas the second paper [109] represents opposing 
evidence. In the latter study, the binding of iodinated Stx1 to isolated human PMN from seven donors 
was shown to be ineffective. Moreover, the authors demonstrated the absence of PMN-binding activity 
of the iodinated B subunits added to whole human blood (7 donors) or injected in mice (9 animals). In 
both cases, most of the radioactivity was found in the plasma. 
There appears to be a real dichotomy on this topic. The binding of Stx to human PMN in vitro has 
been demonstrated experimentally by other three different groups [83,110–114], even though Karpman 
and colleagues found minimal binding of the toxins to neutrophils [83]. This would be expected since 
the authors challenged whole blood with 10–12 M Stx2 concentrations with respect to the 10–9 M 
concentrations required to saturate PMN receptors [99,114]. The positive results on the ability of Stx to 
bind human PMN were obtained with methods based on fluorescent toxins or fluorescent antibodies 
(indirect and direct cytofluorimetric analysis, immunofluorescence) or radioactive-labeled toxins and 
by employing whole blood or isolated PMN. With indirect cytofluorimetric analysis [105] and  
ELISA [115], employing whole human blood and/or isolated PMN, two different groups failed to 
detect such a binding. The matter remains controversial. It is also not established whether Stx binding 
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to PMN can be inferred by the presence of functional modifications in leukocytes after the putative 
interaction with toxins. Several groups found no activation of PMN in terms of expression of 
degranulation markers or integrins on the plasmatic membrane [105,109,116], superoxide  
production [109,117,118] and elastase release [117] in resting or primed PMN. By contrast, a 
degranulation response with subsequent hyporesponsiveness to a second activating (IL-8)  
stimulus [114] and a dose-dependent induction of superoxide with concomitant reduced ability for 
phagocytosis and reduced response to PMA (phorbol myristate acetate) was observed after incubation 
of PMN with Stx [116]. With respect to the indirect evidence, a delaying effect of Stx on the extent of 
spontaneous neutrophil apoptosis was demonstrated first by Liu and colleagues [119] by flow 
cytometry up to 48 h. Again, this result was followed by a confirmatory paper in which the  
PMN-apoptotic delay induced by the toxins was assessed by morphological examination of nucleus 
shape (10 h and 24 h), measure of caspase 3 activity (5 h) and flow cytometric analysis (48 h) [112]. 
However, contradictory results [115,116] obtained with similar cytofluorimetric techniques at 20 h 
have been published. 
In reviewing all the papers dealing with direct and indirect evidence of Stx/PMN interactions, it 
would appear that positive or negative results are not related to the type of toxin variants (Stx1, Stx2) 
used in the different studies. Conversely, it is worth noting that these apparently conflicting papers 
exhibit an intrinsic coherence, i.e., the papers in which evidence has been presented of the binding of 
the toxins to PMN also contained clear indications of functional modifications of leukocytes. 
Contrariwise, those reporting negative results on binding failed to show functional consequences. 
Strikingly, when PMN were studied in patients with HUS, they were found to be activated, 
degranulated and hyporesponsive to other stimuli and delayed in the apoptotic program [104–106]. 
Interestingly, the same PMN features observed in vivo were also noted by the authors who challenged 
PMN from healthy donors with Stx, obtaining positive results (see above). More importantly, those 
who sought the toxins bound on the surface of PMN in HUS patients, by means of indirect 
cytofluorimetric analysis, invariably found them (see below) [83,90,111,120,121]. This strongly 
suggests that Stx are directly responsible for the functional changes observed in the PMN from 
patients, since they are bound to their surface during the natural course of the disease. Other 
explanations of the state of PMN in patients are based on an early Stx-independent activation of PMN, 
related to the inflammatory status of the bowel and of the kidney. It can be argued that a massive 
liberation into the blood of activating pro-inflammatory cytokines from these body sites might activate 
circulating PMN, as happens in sepsis. However, incubation of PMN from healthy donors with plasma 
from HUS patients did not render these leukocytes activated, degranulated or hyporesponsive to other 
stimuli [105], nor were they resistant to apoptosis [104]. Moreover, although PMN from HUS patients 
showed delayed apoptosis and prolonged life-span [104], they would soon disappear from circulation, 
since the half-life of PMN in blood is about 6 to 7 h [122]. Indeed, every day a huge number of PMN 
(1011 cells) enter the blood from bone marrow, replacing the cells that leave blood by transmigration. 
Defective chemotaxis [117] or impaired transmigration [114] of Stx-treated PMN have not been 
observed. In conclusion, it is unlikely that a single stimulus induces the stable activated state of PMN 
in patients. It is more likely that there is a continuous challenge from the long-lasting persistence of 
Stx on the membrane of PMN in HUS patients [120,121] (see below). Thus, the reasons behind the 
discrepancies obtained in the reports dealing with in vitro binding experiments with purified Stx need a 
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further explanation. As suggested [110], the experimental procedures employed to isolate PMN after 
toxin challenge differ somewhat. Two of the groups reporting negative results [109,115] isolated cells 
and removed free unbound toxins by centrifugation on Ficoll layers or Mono-Poly resolving media, 
whereas mild isolation conditions assuring the minimal perturbation of the samples were employed by 
two groups which gave positive results [110–112,114]. The former treatments could have caused the 
detachment of Stx from PMN because of the low affinity of the Stx/PMN interaction, although it 
should be borne in mind that low-affinity binding does not mean a lack of specificity. Indeed, some 
experts in the field have failed to appreciate the relevance of the binding of Stx to a low-affinity 
receptor (Kd = 10−8 M), defining the weak binding to PMN as non-specific and of little biological 
significance. However, PMN possess other receptors capable of specific and low-affinity binding to 
several important molecules. For example, neutrophils during the phagocytosis of opsonised particles 
or the binding to immunocomplexes, are capable of interacting with the Fc portion of some IgG 
subclasses through different Fc receptors whose affinities largely differ depending on the specific 
function required: FcγRI/CD64 (Kd = 10–9 M) also binds to monomeric IgG, whereas FcγRIIA/CD32a 
and FcγRIIIB/CD16b have lower affinity (Kd = 10–7 M) [123–125]. These binding activities are not 
considered to be of little biological significance, rather, they are fundamental to the function of these 
leukocytes. Moreover, most of the papers confirming such a weak Stx/PMN binding also showed 
evidence of specific interactions, as the bound labeled (either fluorescent or radioactive) toxins were 
displayed by an excess of cold homologous Stx [99,112] or the functional consequences of the binding 
was dampened after heat-inactivation [112,116,119] or treatment with monoclonal antibodies to 
Stx [119]. Finally, PMN low-affinity binding might be advantageous in a model based on the transfer 
of the ligand to high affinity target receptors, such as endothelial Gb3Cer. 
Another possible explanation for the discrepancies in the reviewed studies is that toxins prepared in 
different laboratories might be somewhat different. To further our understanding of this matter,  
Table 1 summarizes the different methods of purification of the toxins used in those papers, as well as 
the LPS content of each preparation. First, it is worth noting that the pivotal study demonstrating for 
the first time the binding to PMN [99] and the subsequent study in which some of the authors reversed 
their position [109] both employed Stx1 given by Dr. Karmali (Health, Toronto Canada). However, the 
batches of toxins were not the same (Leo Monnens, personal communication), with possible 
differences in the properties of Stx in the two different preparations. Second, although not all the 
papers reported the amounts of contaminating LPS in Stx preparations, endotoxin ranged from 
femtogram to picogram units/Stx µg (median 1.5 pg/µg, n = 4) in the positive studies, whereas it 
ranged from tens of picogram to ng/Stx µg (median 40 pg/µg, n = 3) in negative studies (Table 1). This 
indicates that contaminating LPS may not be responsible for the functional effects shown in  
Stx-treated PMN in the positive studies, since negative results have been obtained with higher amounts 
of contaminating endotoxin. On the other hand, the very low amount of LPS together with Stx in the 
positive reports renders unlikely a role for a binary Stx/LPS complex, since the calculated molar ratio 
(assuming molecular mass > 104 Da for LPS and 68,000 Da for Stx) is extremely high. Third, and 
more importantly, five positive studies out of six reported short purification schemes in which Stx 
were resolved by different types of affinity chromatography (globotriose-fractogel, Synsorb pK, P1) 
reducing the purification procedure to one or a few steps. Conversely, with one exception, all the 
groups that obtained negative results purified the toxins by multistep methods (4–5 steps) or obtained 
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them from commercial sources (Table 1). Only in one case was the toxin purified by single-step 
affinity chromatography (Table 1).  
Table 1. Synoptical analysis of Stx purification procedures from publications with 
conflicting results on Stx/PMN interactions. 
Paper Toxin Purification scheme a 
LPS b 
pg/µg 
Purification 
method 
Positive results     
Brigotti et al., [112,114] Stx1 
Stx2 
AGl 
AS, AE, AP1 
<3 
<3 
[126] 
[127] c 
Griener et al., [110] Stx1 
Stx2 
ASy 
ASy 
<0.077 
<0.077 
[128] 
[128] 
King et al., [116]  Stx1 AS, AP1 <3 [129] 
Liu et al., [119] Stx2 
rStx2 
CE, HPLC 
Dr. Gondaira (Denka Seiken, Tokyo) 
n.a. 
<0.001 
[130] d 
n.d. 
Stahl et al., [83] Stx2 AP1e n.a. [131] 
Te Loo et al., [99] Stx1 Dr. Karmali (Health, Toronto, Canada)  n.d. n.d. 
Negative results     
Aoki et al., [118] Stx1 
Stx2 
AS, AE, Ch, HPLC 
AS, AE, Ch, HPLC 
<2500<25
00 
[132] 
[133] 
Fernandez et al., [105] Stx1 
Stx2 
Dr. Juniki (Denka Seiken, Nigata, Japan) 
Dr. Juniki (Denka Seiken, Nigata, Japan) 
<40 
<40 
n.d. 
n.d. 
Flagler et al., [115] Stx1 
Stx2 
AS, AE, HA, AG, GF 
AS, AE, AP, AG, PS 
<11 
<11 
[115] 
[115] 
Geelen et al., [109] Stx1 
Stx2 
Dr. Karmali (Health, Toronto, Canada) 
Toxin Technology, Sarasota FL, USA 
n.d. 
n.d. 
n.d. 
n.d. 
Holle et al., [117] Stx1 
Stx2 
Prof. Lord (Warwick University,UK) AGl f 
Toxin Technology, Sarasota FL, USA 
n.d. 
n.d. 
[126] 
n.d. 
a Abbreviations: AE, anion exchange; AG, Affi-Gel blue; AGl, globotriose affinity chromatography; AP1, P1 
affinity chromatography; AS, ammonium sulfate precipitation; ASy, Synsorb pK affinity chromatography; 
CE, cation exchange; Ch, chromatofocusing; HA, hydroxyapatite chromatography; HPLC, high-performance 
liquid chromatography; PS, Phenyl-Sepharose; n.a. not applicable since the LPS content was reported in 
volume and not per toxin amount; n.d. not done; b To compare data from different papers, the conversion 
from CSE potency of LPS to LPS amount was performed according to the ratio Eu/ng = 13; c Modified by 
[127]; d Modified by [130]; e Dr. D. Karpman’s (Lund University, Lund, Sweden) and Dr. A. Kane’s (Tufts 
Medical Center, Boston, USA) personal communications; f Prof. M. Lord’s (University of Warwick, 
Coventry, UK) personal communication. 
All the recognized methods listed in Table 1 seem sound and ensured purification to homogeneity 
and preservation of the enzymatic and toxic activity of Stx as directly assessed by the authors of the 
studies and/or as reported in the references covering the purification methods. Thus, the conclusions 
reached by the authors of the negative papers were not incorrect: fully-active toxins with no  
binding-activity for PMN. However, we recently made the serendipitous observation that it is possible 
to obtain fully toxic Stx1 lacking PMN binding activity [134]. By means of spectroscopic and 
fluorescence techniques, our group demonstrated that a partial unfolding of the toxin, with reduction of 
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α-helix content and exposure of some hydrophobic Trp residues led to loss of PMN binding 
activity [134]. Interestingly, the enzymatic activity linked to the A chain and the Gb3Cer binding 
activity related to B chains were preserved and the unfolded toxin was found to be fully active in 
intoxicating human endothelial cells [134]. The loss in PMN-binding activity was partially reproduced 
by repeated freeze and thawing cycles, with conservation of toxic activity [134]. In conclusion, a 
reasonable explanation of the conflicting results regarding Stx/PMN interactions would be a partial 
conformational change of toxins prepared by more complicated and laborious multi-step purification 
methods. Obviously, these methods have been set-up to obtain pure Stx endowed with full cytotoxic or 
enzymatic activities, rather than adapted to the recovery of the then unknown PMN-binding activity. 
For this reason, we have proposed that purified toxins should also be assayed for correct folding, by 
inspecting circular dichroism and/or fluorescence emission spectra and their maxima.  
5. PMN Recognize the A Chain of Stx and Related Plant Toxins 
Several lines of evidence indicate that the interactions between Stx and PMN are mediated by the  
A chain of the toxins. Competition experiments clearly showed that the PMN-binding domain on Stx is 
distinct from the Gb3Cer-binding domain. Indeed, the binding of Stx to human PMN in vitro is 
strongly increased by “DAISY” (a decavalent Gb3-related receptor analogue), which however inhibits 
Stx binding to Gb3Cer-expressing eukaryotic cells [110] and prevents Stx-induced lethal effects on 
mice [135]. Moreover, human serum amyloid P component (HuSAP) was found to bind specifically to 
Stx2 [136,137] and to inhibit the Gb3Cer-related cytotoxic activity of this toxin [136], protecting mice 
from its lethal effects [138]. Indeed, this putative competitor failed to inhibit and rather increased toxin 
binding to human PMN [110]. It should be noted that “DAISY” and HuSAP inhibited the binding 
of Stx to murine [110] neutrophils endowed with Gb3Cer receptors also found in porcine [139]  
and ovine [140] granulocytes. Thus, Stx interact with murine, porcine and ovine PMN via  
Gb3Cer-dependent mechanisms, while Gb3Cer-independent mechanisms are operative in mediating  
Stx-binding to human PMN. This is consistent with the notion that human PMN do not possess the 
complete repertoire of enzymes necessary to synthesize glycosphingolipids of the globo-series, such as 
Gb3Cer [141]. Further support is provided by results obtained in the human myeloid leukemia cell  
HL-60 model for inducible cell differentiation [142,143]. These undifferentiated cells only possess 
trace levels of Gb3Cer [144] and do not bind Stx [112]. Conversely, differentiation of HL-60 to 
granulocytes by treatment with all-trans-retinoic acid, a condition which does not up-regulate Gb3Cer 
expression [145,146], enabled the cells to bind Stx [112]. The same behavior was observed with poorly 
differentiated immature human granulocytes obtained by healthy donors treated with G-CSF that, 
unlike mature PMN, do not bind Stx [112].  
Taken together, these results indicate that mouse and human PMN differ in the expression and in 
the nature of Stx-binding receptors. The results obtained in mouse models on the delivery of toxins in 
blood [109,115] cannot, therefore, be considered representative of the toxic delivery pathways in HUS 
patients, even though they might be useful to mimic HUS renal damage and test the efficacy of new 
therapeutic approaches [147–149]. Moreover, in light of the evidence reported above, the negative 
results on PMN-binding obtained with isolated Stx B subunits in human blood can be considered a 
further proof of the involvement of A subunit [109].  
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Direct evidence of the binding to human PMN of Stx A subunit isolated by fast protein liquid 
chromatography has been presented [110], and this important contribution was the first report of the 
binding of the enzymatic chain of Stx to an eukaryotic cell. This behavior of the Stx A chains was 
confirmed by competition experiments showing that the A chain of ricin and two single-chain RIPs, 
gelonin (from the seeds of Gelonium multiflorum) and the non-glycosylated saporin S6 (from the seeds 
of Saponaria officinalis) impaired the binding of Stx to PMN, whereas diphtheria toxin was 
completely ineffective [113]. This is in keeping with the notion that A chains of ricin and Stx show 
structural similarities [28,29]. As such, the interaction of fluorescent ricin A chain with human PMN 
has been demonstrated directly by flow cytometric analysis: the binding is saturable, specifically 
inhibited by cold ricin A chain and the fluorescent subunit was not internalized by leukocytes [113] as 
well as Stx [99]. The calculation of the Kd value (10−9 M) and the number of binding sites of the ricin 
A chain/PMN interaction showed that the affinity of ricin A chain for PMN was 10-fold higher than 
that reported previously for Stx, while the number of binding sites per cell was of the same order of 
magnitude as those calculated for the Stx/PMN interaction [99,112]. Taken together, these 
observations indicate that Stx/PMN interactions are specific. Moreover, the fact that Stx and related 
plant toxins share, apart from structural similarities and identical enzymatic activity, a common 
receptor on PMN changes our perspective somewhat. It is not a simple interaction with eukaryotic 
cells to be targeted and killed by powerful toxins belonging to quite different biological kingdoms, but 
rather involvement of an actor of the innate immunity, the PMN, that recognize a class of dangerous 
potent toxins irrespective of the source. This is consistent with the known ability of these leukocytes to 
recognize molecular patterns common to different foreign molecules. The implications of such a 
binding in PMN of patients with HUS merit some discussion (see next paragraph). 
Finally, other deductions on the PMN-binding site on Stx arise from the experiments reported above 
with unfolded toxin with impaired binding but fully active as toxic agent [134]. Unfolded Stx1 showed 
disruption of α-helix structures with exposure of Trp residues otherwise residing in hydrophobic 
environments in native toxin. From steady state and time resolved fluorescence studies and by 
reviewing functional and structural data, it is possible to identify the A chain moieties close to Trp203 
and located in the A1 fragment as the region recognized by PMN. As stated above, the A1 fragment is 
the portion of Stx which possesses highly similarity with ricin A chain in primary sequence and 
secondary structure (Figure 1). In conclusion, the presence of a new binding site for PMN in the Stx A 
subunit, besides the enzymatic-active site and the well-known Gb3Cer-binding sites in the B subunits, 
represents a novel property of these well-characterized bacterial toxins.  
6. Transfer of Stx from PMN to Gb3Cer-Expressing Cells 
The idea of circulating PMN as toxin carriers was first proposed by [99] based on experiments in 
which co-incubation of human glomerular microvascular endothelial cells with PMN carrying Stx 
resulted in the transfer of the toxin to the former cells. The data were obtained with fluorescent toxin, 
by monitoring the transfer by flow cytometry (fluorescent staining of 30% of endothelial cells and 
disappearance of fluorescence on PMN), and with native toxin, by measuring Stx-induced cytotoxicity 
and translation inhibition in targeted cells. The transfer was confirmed in similar experiments 
performed with PMN carrying fluorescent Stx and Ramos cells which express Gb3Cer receptors [110]. 
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However, these important data were obtained in experimental models that did not reproduce the 
physiological mode of interaction of circulating PMN with endothelia. These interactions mainly occur 
in post-capillary venules, whereas the renal glomerulus is one of the few sites in which PMN 
recruitment occurs in capillaries [150]. Although PMN travelling in capillaries are close to the inner 
surface of the vessels, their interactions with endothelial cells are accidental and scanty in normally 
flowing blood, since they mainly occur during leukocyte transmigration in the presence of 
chemoattractants. By using an experimental model consisting of a confluent monolayer of human 
umbilical vein endothelial cells through which endotoxin-free PMN transmigrate, recruited by IL-8, it 
has been demonstrated that PMN diapedesis is not impaired by the presence of Stx on their membrane, 
even under saturating conditions [114]. While non-transmigrating PMN transferred only low amounts 
of toxins, during 2 h-transmigration Stx passed from PMN to endothelial cells, as shown by the 
disappearance of unlabeled or radioactive toxins from transmigrated PMN and by the concomitant 
radioactive labeling of the endothelium [114]. After overnight post-incubation, endothelial cells 
became intoxicated as assessed by the extent of translation inhibition which, in turn, depended on the 
number of transmigrating leukocytes carrying Stx. The addition of monoclonal antibodies to Stx during 
transmigration prevented endothelial cell intoxication, demonstrating the specificity of such a transfer.  
It should be noted that the observations obtained in in vitro experimental models of pathogenesis, 
although controlled and accurate, need to be validated in animal models and directly observed in 
patients, before concluding that they are really operative during the natural course of the disease. Thus, 
the demonstrated transfer of Stx from circulating cells to endothelia in vitro is still a suggestive 
hypothesis. The baboon model may constitute a relevant test, since these animals, unlike other animal 
models such as mice, have probably the same expression of Stx-receptors on PMN as humans. 
However, an improved animal model using baboons with intestinal infection by STEC would more 
accurately reproduce the course of the human condition during the passage of freshly produced toxins 
through the epithelial barrier into the circulation.  
7. Where Do PMN Bind Stx During the Natural Course of Disease? 
This can be studied by analyzing the affinity properties of the toxins with respect to PMN and/or by 
reviewing the notions on the presence of Stx in the blood of patients (see next paragraph). The number 
of Stx or ricin A chain receptors on PMN is approximately 2 × 105 [99,113], accounting for the 
presence of about 1 fmol of toxins on 3000 saturated PMN in 1 µL of blood. However, the Kd of the 
toxin/PMN interactions are quite different in the case of the plant (10–9 M) or the bacterial toxin (10–8 M). 
The one order of magnitude difference means that relevant amounts of ricin A chain molecules are 
captured by PMN when they are challenged with toxin concentrations equal to or below the  
Kd (≤1 nM, Table 2) and that the amount of ricin A chain bound to PMN at full saturation of receptors 
is in equilibrium with a 10-fold excess of free ricin A chain (Table 2). In the case of Stx, however, the 
toxin saturating PMN receptor is in equilibrium with a 100-fold concentration of free toxin (Table 2). 
Moreover, free toxins largely exceed bound toxin (10–20 fold) at Stx concentrations equal to or lower 
than the Kd (≤10 nM, Table 2).  
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Table 2. Theoretical analysis of the relationship between saturation of PMN receptors, free 
toxins and PMN-bound toxins. 
Total toxin 
(nM) 
Stx1 a Ricin A chain a 
PMN receptor 
saturation (%) 
Free 
toxin (%) 
Bound 
toxin (%) 
PMN receptor 
saturation (%) 
Free  
toxin (%) 
Bound  
toxin (%) 
100 90.83 99.09 0.91 - - - 
10 48.75 95.12 4.88 90.10 90.99 9.01 
1 8.39 91.61 8.39 38.20 61.80 38.20 
0.1 0.90 90.98 9.02 4.88 51.25 48.75 
0.01 0.09 90.92 9.08 0.50 50.12 49.88 
0.001 0.01 90.91 9.09 0.05 50.01 49.99 
a The data have been calculated according to the parameters obtained by Scatchard plot on the PMN/ricin A 
chain (Kd = 10–9 M; binding sites = 2 × 105) [113]; or PMN/Stx1 (Kd = 10–8 M; binding sites = 2 × 105) 
[99,112] interactions assuming the presence of 3000 PMN/µL of blood. 
If Stx/PMN interactions are not perturbed in vivo by other factors and assuming that PMN 
encounter Stx in blood, this means that it is not possible to detect PMN-bound Stx in the absence of 
free toxins in circulation. This is in contrast with the clinical observations in patients with HUS, which 
indicate the presence of Stx on PMN in the absence of free toxin. In fact what happens in the lamina 
propria of the gut during the translocation of Stx in blood is complicated by the contemporaneous 
presence of resident (gut endothelial cells) and circulating (monocyte and platelets) cells harboring 
high-affinity Gb3Cer receptors. The areas of the bowel colonized by STEC are rather restricted with 
respect to the surface of gut endothelia. It is likely that Stx concentrations may be quite elevated, and 
probably sufficient to engage circulating PMN in the intestinal vessels supplying those areas of the 
bowel where toxin translocation occurs. Moreover, the concomitant inflammatory process of the gut 
might slow blood flow (stasis) increasing the time of engagement of PMN with toxins. In contrast, 
non-activated monocytes and platelets are probably poor competitors, since they possess few receptor 
copies despite their high affinity (see above). However, the concentration of free Stx locally elevated 
in blood supplying the STEC-colonized bowel sites during toxin translocation is bound to be reduced 
as the blood flows through other gut vessels, simply because of the huge amount of Gb3Cer receptors 
encountered on the enormous intestinal endothelial surface. Thus, blood refluxing from gut might 
contain PMN, carrying the toxins and low amounts of free Stx. In a short time the blood ejected by the 
heart completes its journey round the body together with passenger PMN. Therefore, when fresh toxins 
are present in the gut and continuously cross the epithelial intestinal barrier, PMN can progressively 
raise their receptor saturation until they or Stx disappear from the blood. 
Another possible explanation might be that PMN encounter the toxins outside the circulation during 
the gut inflammation that follows the Stx-induced injury of the intestinal endothelial cells. The influx 
of neutrophils into the intestinal lamina propria and in the crypts of patients with HUS has been 
reported [77,151–153] and the inflammatory transmigration of PMN enhanced the translocation of Stx 
across intestinal epithelial cells [76]. Thus, PMN are found close to the basal surface of gut epithelial 
cells during the passage of toxins from the intestinal lumen. PMN carrying Stx could survive in the 
exudates, as they show a delay in the apoptotic program, being removed subsequently by lymphatic 
drainage eventually reaching the bloodstream. However, this last explanation seems unlikely since an 
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abundant influx of PMN in the intestine, which can justify the mechanism of carriage of these 
leukocytes, was only observed in HUS cases in which the colon is severely involved. 
8. Binding of Stx to PMN in Patients with HUS 
After the first demonstration of the direct interaction Stx/PMN, Monnens’ group undertook a 
careful clinical study designed to demonstrate the role of such an interaction in HUS [120]. By means 
of indirect flow cytometry on PMN isolated from 11 patients with HUS, they found Stx on most of 
them. The binding was shown to be specific for PMN, as other circulating cells from those patients 
(lymphocytes, monocytes, erythrocytes) were negative with the exception of activated monocytes in a 
later phase of the disease [120]. They also observed that the percentage of positive PMN in patients 
decreased over time up to five days [120]. These clinical data were considered an important extension 
of the first observations in vitro, and a main contributor in comprehending the pathogenesis of HUS. 
Subsequently, the indirect flow cytometric method used for the detection of Stx bound to patients’ 
PMN [120] was adapted to white blood cells, isolated after erythrocytic lysis from whole blood, thus 
avoiding the complex procedure of PMN isolation [111]. PMN were easily recognized by gating them 
on morphology and by staining with monoclonal antibodies that react with granulocyte antigens CD16 
and CD65. The new very rapid (few hours) and sensitive (femtomoles of toxin) version of the 
detection method also addressed the problem of false positive results, possibly due to direct interaction 
with PMN of mouse monoclonal antibodies specific for Stx. The addition to the assay of human serum 
to saturate Fc receptors avoided false positive Stx detection [111]. The drawback of this method is 
represented by the cross-reactivity of the mouse monoclonal antibodies to Stx1 (13C4) and Stx2 
(BB12), which thus cannot discriminate the two toxin variants. These monoclonal antibodies, tested 
for the ability to neutralize toxin-induced cytotoxicity [59,127] or to inhibit the toxin-induced release 
of adenine from DNA (our unpublished observations), did not cross-react in reciprocal titrations of the 
two toxins. However, with respect to the latter assays in which toxins are free in solution, the situation 
is complicated by the presence of PMN during the cytofluorimetric assay. In the latter case, these 
antibodies must recognize the toxins present in binary (Stx1/receptor) or ternary 
(Stx2/HuSAP/receptor) complexes [110] and this might in part explain the cross-reactivity 
phenomenon.  
The kinetics of Stx in blood by this method and in feces by Vero cell cytotoxicity assay during the 
natural course of the disease was evaluated in a further study [121], showing a positive correlation 
between the amount of toxin detected in stools and the amount of Stx on PMN. In HUS patients a  
half-life of four days of Stx in blood was calculated and, surprisingly, toxins were still detectable in 
PMN for a median period of five days after they were no longer detectable in stools [121]. Although 
Stx-positive PMN show delayed apoptosis [112,119], they are not impaired in transmigration [114], 
hence in patients they must disappear from the blood within a few hours. However, in vitro  
co-incubation of fully-loaded PMN with empty PMN leads to the transfer of the toxic ligand between 
neutrophils [112]. Thus, it could be argued that in patients the Stx are transferred from old neutrophils 
to new mature cells entering the circulation from the bone marrow, in a sort of a relay race, extending 
the blood half-life of the toxins beyond the blood half life (6–7 h) or the life-span (1–2 days) of these 
cells. The implication of this long-lasting blood detection of Stx in the diagnosis of HUS and in 
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defining the infective etiology is clear, since the windows of tests aimed at detecting Stx or STEC in 
feces are shorter.  
Since the cytofluorimetric assay used in the above-mentioned studies also provides a quantitative 
evaluation of the toxins bound to PMN, the relationships between the clinical course of HUS in 
patients and the amount of Stx detected in their blood samples have been sought [90]. In this study, 
patients with Stx-positive PMN (about 60%) were divided into two groups according to the saturation 
of Stx receptor in their PMN. Although no significant differences were observed in platelet and 
neutrophil counts, significant differences were observed in renal function: cases with high Stx levels 
on PMN (full receptor saturation) had slightly altered serum creatinine concentrations, whereas 
children with low Stx levels (about 1/3 receptor saturation) had values above the upper limit for age 
over several days during hospitalization. Moreover, patients with high Stx levels required less frequent 
dialysis with a shorter duration of dialytic treatment. These observations, albeit paradoxical, are 
consistent with those obtained in baboons challenged with intravenous infusion of high and low doses 
of Stx1 [154]. Although the animals belonging to both groups showed acute renal failure, the 
histopathological changes in the kidney were less pronounced in those animals challenged with high 
concentrations of toxin and which had no evidence of thrombotic microangiopathy in 60% of 
glomeruli. The low-dose group exhibited thrombotic microangiopathy in more than 90% of glomeruli 
accompanied by endothelial swelling (about 40%) and combined endothelial swelling and red 
corpuscle fragmentation (about 40%). The authors concluded that these findings reflected the picture 
observed in childhood post-diarrheal HUS [154]. Interestingly, in the same study, autopsies revealed 
edema of the brains of animals injected with the high-dose, whereas the brains of low-dose group 
exhibited a normal gross appearance and weight. Consistently, neurological complications were 
observed more frequently in HUS patients with high circulating levels of Stx on PMN [90]. The same 
behavior can be observed if the clinical data reported in the Monnens’ study on HUS patients 
described above [120] are stratified according to the amounts of toxins on PMN. In the Monnens’ 
study the saturation of toxin receptor on PMN was not reported, since the authors preferred to indicate 
the percentage of positive PMN over the whole cellular population. As shown in Table 3, by using this 
parameter and following the criteria indicated in [90] for the categorization of patients, the correlations 
between the two studies are clear-cut.  
Table 3. Clinical data a of patients with HUS and PMN positivity to Stx. 
 High % 
Stx-positive PMN 
(mean ± SD, n = 4) 
Low % 
Stx-positive PMN 
(mean ± SD, n = 3) 
t Test 
Creatinine (µM) 229 ± 124 627 ± 219 p < 0.05 
Hb concentration (M) 5.0 ± 1.3 4.2 ± 1.8 p = 0.52 
Platelets × 109/L 36.3 ± 14.6 64.7 ± 28.2 p = 0.14 
a Stratification of the clinical data (first determinations) of patients in [120] following the criteria in [90]:  
cut-off ≤ 5%; low percentage of Stx-positive PMN >5% to 35%; high percentage of Stx-positive  
PMN > 35%). 
No significant differences were observed in platelet counts and hemoglobin concentrations, whereas 
an inverse relationship between creatinine concentrations and percentage of positive PMN emerged: 
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the lower the percentage of positive PMN, the higher the creatinine concentration (Table 3). 
Unfortunately, a patient with a low creatinine on presentation died during the study from neurological 
complications. This was indeed the patient with the high (96%) and most persistent percentage (92% 
after 5 days) of positive PMN, i.e., a high-dose patient according to the findings of the more recent 
clinical study [90] and the data obtained with baboons [154]. However, by only analyzing the data in 
Table 3 one cannot draw conclusions about the severity of the HUS in those patients, since the original 
paper [120] did not report all the obvious complex clinical data recorded for each patient during their 
hospitalization. On the other hand, the main clinical characteristics reported in that study [120] support 
the idea [90] that the detection of the amounts of Stx on PMN might help clinicians identify patients at 
particular risk of neurological complication or with more relevant renal involvement. 
Some years later, the same Dutch authors tried to explain the unreliability of their in vitro data on 
Stx binding to PMN, also casting some doubt on their clinical study, and in particular on the specificity 
of the cytofluorimetric assay for Stx detection on PMN [109]. They showed that 11 out of 16 patients 
without any symptoms of HUS, but needing hemodialysis, were positive to the cytofluorimetric assay 
for Stx detection, possibly for the known activation of PMN caused by this dialytic treatment [109]. 
Healthy control and non-HUS patients undergoing peritoneal dialysis were negative. Surprisingly, in 
the clinical study they had presented only patients undergoing peritoneal dialysis [120], a treatment 
which they considered safe for the detection of Stx on PMN [109], hence artefacts in Stx detection on 
PMN related to dialysis may also be excluded in their clinical study. It should be noted that another 
paper by the same authors aimed at detecting Stx on PMN of households of children with HUS showed 
that several persons living with patients had positive PMN even though they did not require any 
dialytic treatment [155]. This is consistent with the notion that only a low percentage of STEC-infected 
humans develop HUS and indicates a lack of correlation between dialytic treatment and detection of 
Stx bound to PMN. Consistently, a subsequent paper failed to confirm any correlation between 
positive cytofluorimetric assays and concomitant hemodialysis [90].  
The inverse or direct relationship between the amount of toxins on PMN and renal or cerebral 
involvement is rather enigmatic. Various hypotheses can be advanced: (i) circulating PMN might 
capture free toxins preventing their binding to renal endothelium (sponge effect) but not to cerebral 
endothelium; (ii) the amounts of Stx on PMN membrane could reflect the differential avidity for toxins 
of renal endothelia but not of cerebral endothelia; (iii) PMN shuttle the gut-associated toxins to the 
kidney and brain but the endothelial responses to intoxication might be inversely related to the 
amounts of toxins delivered to renal endothelia and directly related in the case of cerebral endothelia.  
The last explanation is in agreement with previous observations in vitro. PMN loaded with different 
amounts of Stx, comparable with those observed in HUS patients, induced strikingly different 
responses in endothelial cells in terms of survival and production of pro-inflammatory cytokines [114]. 
Experimental transmigration of PMN carrying low amounts of Stx caused a relevant but not total 
inhibition of protein synthesis in endothelial cells and triggered a strong up-regulating effect on IL-8 
and MCP-1 release without any effect on cell viability. Conversely, the transmigration of PMN with 
full saturation of Stx receptors almost completely blocked translation in endothelia with the 
concomitant impairment of IL-8 and MCP-1 induction and triggering of the apoptotic program (see 
also Figure 2). Therefore, patients with high Stx levels in PMN may develop sudden endothelial 
injuries that trigger apoptosis in intoxicated cells, without producing the slow self-amplifying  
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pro-inflammatory cycle which might induce glomerular damage in the kidney. Notably, in the baboon 
model described above, the production of pro-inflammatory mediators was localized in the renal  
tissues [154] and high levels of urinary pro-inflammatory mediators in patients did not correlate with 
their blood levels [156,157].  
The picture might be quite different when PMN-bearing toxins reach the blood-brain barrier which 
segregates blood and interstitial fluid. Brain capillary endothelial cells, unlike the fenestrated capillary 
in the kidney, are cemented by tight junctions [158] and interact intimately with astrocyte foot 
processes to form a barrier that selects and regulates transport of molecules in the central nervous 
system [159]. Sudden brain endothelial injuries imposed by large amount of toxins on PMN, rather 
than a slowly self-amplifying pro-inflammatory cycle as in renal endothelia, might well alter the 
delicate equilibrium of selective transport across the blood-brain barrier, eventually inducing the 
neurological complications observed in patients. Rabbit models of neuropathogenesis corroborate this 
hypothesis since intravenously injected Stx2 disrupted the blood-brain barrier [160]. The mechanism 
proposed is based on neuronal apoptosis caused by activated microglial cell [161]. Astrocytes 
activation may be secondary to endothelial damage and microvascular thrombosis induced by Stx in 
brain circulation [63]. 
9. The Nature of the Stx-Recognizing Receptors on PMN 
Innate immunity, of which PMN are main actors, was regarded for a long time as a relatively  
non-specific system, with its main role being the killing of pathogens by phagocytosis and related 
mechanisms. In the past decades, the scenario has completely changed since several studies have 
revealed that the innate immune system possesses a high degree of specificity and is capable of 
discriminating between self and foreign pathogens at the molecular level. In fact, PMN, as well as 
macrophages, recognize molecular signatures common to different microorganisms but not to the host, 
which have been broadly defined as pathogen-associated molecular patterns (PAMPs). PMN recognize 
PAMPs by means of membrane or cytoplasmic receptors, called pattern-recognition receptors (PRR),  
such as Toll-like receptors (TLRs), C-type lectins receptors, NOD-like receptors and RIG-I-like  
receptors [162,163]. Some of these receptors are good candidates for membrane molecules capable of 
interacting with a class of different but analogous toxins, i.e., Stx and related plant toxins. The 
interaction between PAMPs and a single PRR, although specific, is characterized by the recognition of 
a divergent collection of ligands, and the bound molecules are not necessarily internalized as is found 
for the Stx/PMN and the ricin A chain/PMN interactions. It is rather more an activation of a response 
leading to the production of cytokines required for the development of immunity and subsequent 
destruction of the pathogens. As stated above, PMN in HUS patients are activated and their functional 
state in the acute period of HUS is inversely correlated with the severity of renal damage: PMN from 
patients with the highest degree of renal failure showed the lowest level of markers of degranulation, 
intracellular myeloperoxidase and reactive-oxygen species production [104]. Clearly, identification of 
the nature of receptor would be the ultimate goal, and a recent study eliminated a number of receptor 
candidates since agonists of some TLRs (TLR1, TLR2, TLR5, and TLR6) or the mannose receptor are 
completely ineffective in displacing Stx from PMN in competition experiments [113]. Conversely, 
TLR4 improves the binding of Stx to primary human umbilical vein endothelial cells, indicating that it 
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may also be exploited by bacterial toxins to interact with PMN [164], even though we lack evidence at 
the present time. TLR4 seems a good candidate since it is capable of interacting not only with LPS and 
the plant diterpene paclitaxel, but also with several proteins (fusion protein of respiratory syncytial 
virus, fibronectin and heat-shock proteins) [165]. A validation of this attractive hypothesis awaits the 
direct demonstration of the interaction Stx/TLR4 in human PMN. 
10. Conclusions 
The Stx/PMN interaction might resemble a double-edged sword since higher amounts of Stx on 
PMN might protect patients from acute renal failure, while contributing to neurological complications. 
It is not surprising, since neutrophils play a definite role in protecting hosts through their cooperation 
in innate and adaptive immunity. However, they also play a crucial role in the pathogenesis of 
numerous diseases [166]. Understanding the mechanisms of Stx delivery in blood, in particular the role 
of Stx bound to PMN or the role of free toxins, should help to develop evidence-based therapeutic 
strategies for preventing the onset of HUS or attenuate its clinical expression. Plasma exchange would 
be the elective therapy for clearing free plasmatic toxin, while the prevention of PMN/endothelium 
interactions with available drugs (selectin inhibitors, integrin inhibitors, chemoattractant receptor 
inhibitors) would be useful for PMN-bound Stx. However, a modification of the current standard of 
HUS management from purely supportive treatment to curative strategies requires clarification of the 
mode of delivery of the toxins in blood from studies on patients in the prodromal gastrointestinal 
phase, rather than on patients with overt HUS. In Italy, in 2010, a network connecting pediatricians, 
the Center for HUS control in Milan and the Regione Lombardia was set up for early enrolment of 
children with STEC-associated bloody diarrhea. This allows the study of the kinetics of Stx in the 
feces and blood of these patients by a daily sampling until recovery to focus on the crucial step of the 
transition between hemorrhagic colitis and HUS. It should be noted that in a recent Argentinean study 
this has been partially addressed [167] by screening about 2500 cases of diarrhea in humans for STEC 
infections. Almost 100 patients with STEC-associated gastroenteritis were enrolled and, during the 
observational study, 8 of them developed HUS. By means of a new validated ELISA the authors found 
free Stx2 in the sera of five patients who did not developed HUS and in three of those who developed 
HUS. Interestingly, the toxin appeared in blood just after the onset of diarrhea for a short time (48–72 h) 
and then disappeared before the development of HUS. This is consistent with the absence of detectable 
toxin in the sera of HUS patients reported in several studies [52,89,90]. However, in the Argentinean 
study no attempts were made to seek the presence of Stx on PMN. Moreover, five patients developing 
overt HUS were found negative for the detection of free Stx2 in sera during the prodromal phase, and 
no pathogenic mechanism was proposed. It is clear that this aspect of HUS pathogenesis is puzzling. 
What could be the crucial step in the transition between hemorrhagic colitis and HUS: the simple 
presence of Stx in blood, their amounts on PMN and/or their presence in plasma with subsequent rapid 
clearance, the presence of discrete peaks of toxins or a long-lived toxemia with lower toxin amounts? 
Only carefully conducted studies in patients in the prodromal phase of HUS or in well-suited animal 
models designed to identify, without any preconception, the pathogenetic process of HUS on the basis 
of our current knowledge, even though obtained in often conflicting reports, will be able to achieve 
this goal. 
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